RS51194B - Formulacija tienopiridina kao inhibitora agregacije plateleta - Google Patents

Formulacija tienopiridina kao inhibitora agregacije plateleta

Info

Publication number
RS51194B
RS51194B RSP-2009/0425A RSP20090425A RS51194B RS 51194 B RS51194 B RS 51194B RS P20090425 A RSP20090425 A RS P20090425A RS 51194 B RS51194 B RS 51194B
Authority
RS
Serbia
Prior art keywords
formulation
thienpyridine
platelet aggregation
aggregation inhibitor
moisture
Prior art date
Application number
RSP-2009/0425A
Other languages
English (en)
Inventor
David Brian Dziennik
Tamara Beth Edelman
Peter Lloyd Oren
Robert Louis Ternik
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37198935&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS51194(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of RS51194B publication Critical patent/RS51194B/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

Formulacija naznačena time što uključuje terapeutski efektivnu količinu jedinjenja formule Ipakovanu u blister pakovanje sa inertnim gasom koji onemogućava prisustvo vazduha i vlage.Prijava sadrži još 13 zavisnih patentnih zahteva.
RSP-2009/0425A 2005-06-10 2006-06-06 Formulacija tienopiridina kao inhibitora agregacije plateleta RS51194B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68918305P 2005-06-10 2005-06-10
PCT/US2006/021860 WO2006135605A2 (en) 2005-06-10 2006-06-06 Formulation of a thienopyridine platelet aggregation inhibitor

Publications (1)

Publication Number Publication Date
RS51194B true RS51194B (sr) 2010-10-31

Family

ID=37198935

Family Applications (1)

Application Number Title Priority Date Filing Date
RSP-2009/0425A RS51194B (sr) 2005-06-10 2006-06-06 Formulacija tienopiridina kao inhibitora agregacije plateleta

Country Status (35)

Country Link
US (1) US20080176893A1 (sr)
EP (1) EP1896019B1 (sr)
JP (1) JP2008543755A (sr)
KR (2) KR20100076050A (sr)
CN (1) CN101193633B (sr)
AR (1) AR054283A1 (sr)
AT (1) ATE441413T1 (sr)
AU (1) AU2006258102B2 (sr)
BR (1) BRPI0611350B8 (sr)
CA (1) CA2611668C (sr)
CY (1) CY1109502T1 (sr)
DE (1) DE602006008942D1 (sr)
DK (1) DK1896019T3 (sr)
DO (1) DOP2006000126A (sr)
EA (1) EA011693B1 (sr)
EC (1) ECSP077984A (sr)
ES (1) ES2330373T3 (sr)
HK (1) HK1116422A1 (sr)
HR (1) HRP20090516T1 (sr)
IL (1) IL187830A0 (sr)
MA (1) MA29688B1 (sr)
MX (1) MX2007015431A (sr)
MY (1) MY151038A (sr)
NO (1) NO20076317L (sr)
NZ (1) NZ564003A (sr)
PE (1) PE20070320A1 (sr)
PL (1) PL1896019T3 (sr)
PT (1) PT1896019E (sr)
RS (1) RS51194B (sr)
SI (1) SI1896019T1 (sr)
TN (1) TNSN07466A1 (sr)
TW (1) TWI318571B (sr)
UA (1) UA91051C2 (sr)
WO (1) WO2006135605A2 (sr)
ZA (1) ZA200710697B (sr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0720248A2 (pt) * 2006-12-07 2013-12-31 Lilly Co Eli Artigo de fabricação de prasugrel
TWI428151B (zh) * 2006-12-07 2014-03-01 Daiichi Sankyo Co Ltd 含有甘露醇或乳糖之固形製劑
US20100280064A1 (en) * 2006-12-07 2010-11-04 Tomoyuki Watanabe Pharmaceutical composition having improved storage stability
CA2672157C (en) * 2006-12-07 2016-07-26 Daiichi Sankyo Company, Limited Method for producing solid preparation
TWI482641B (zh) 2006-12-07 2015-05-01 Daiichi Sankyo Co Ltd 含有低取代度羥丙基纖維素之醫藥組成物
EP2100606A4 (en) * 2006-12-07 2009-12-30 Daiichi Sankyo Co Ltd COATED PREPARATION OF A FILM HAVING IMPROVED STABILITY
DK2123656T3 (da) * 2007-03-02 2014-09-08 Daiichi Sankyo Co Ltd Fremgangsmåde til fremstilling af prasugrelhydrochlorid med høg renhed
KR20150041173A (ko) 2007-04-27 2015-04-15 사이덱스 파마슈티칼스, 인크. 클로피도그렐 및 설포알킬 에테르 사이클로덱스트린을 함유하는 제형 및 사용 방법
GB2450117A (en) * 2007-06-13 2008-12-17 Reckitt Benckiser Healthcare A water- and oxygen-occlusive blister tablet pack
DE112009000268T5 (de) 2008-02-06 2011-06-01 Helm Ag Prasugrel-Salze mit verbesserten Eigenschaften
EP2107061A1 (en) * 2008-04-02 2009-10-07 Krka Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of optically enriched clopidogrel
DE602008002820D1 (de) 2008-04-25 2010-11-11 Sandoz Ag Hydrogensulfat von 2-Acetoxy-5-(a-cyclopropylcarbonyl-2-fluorbenzyl)-4,5,6,7-tetrahydrothienoÄ3,2-cÜpyridin und dessen Zubereitung
SI2398468T1 (sl) * 2009-02-17 2017-03-31 Krka, D.D., Novo Mesto Farmacevtske sestave, ki obsegajo prasugrel ali njegove farmacevtsko sprejemljive kislinske adicijske soli in postopek za njihovo pripravo
KR101991367B1 (ko) 2009-05-13 2019-06-21 사이덱스 파마슈티칼스, 인크. 프라수그렐 및 사이클로덱스트린 유도체를 포함하는 약학 조성물 및 그의 제조 및 사용 방법
DE102009036646A1 (de) 2009-08-07 2011-02-10 Ratiopharm Gmbh Prasugrel in nicht-kristalliner Form und pharmazeutische Zusammensetzung davon
WO2011052499A1 (ja) * 2009-10-28 2011-05-05 第一三共株式会社 貯蔵安定性が改善された医薬組成物
JP2013032289A (ja) * 2009-10-28 2013-02-14 Daiichi Sankyo Co Ltd ワックス安定製剤
WO2011092720A2 (en) * 2010-02-01 2011-08-04 Msn Laboratories Limited Pharmaceutical composition of prasugrel and its pharmaceutically acceptable salts
EP2409685A3 (en) 2010-07-19 2012-02-01 Sanovel Ilac Sanayi ve Ticaret A.S. Orally-disintegrating formulations of prasugrel
TR201006802A1 (tr) * 2010-08-17 2012-03-21 Sanovel İlaç San. Ve Ti̇c. A.Ş. Prasugrelin oral yolla dağılan formülasyonları.
TR201005900A1 (tr) 2010-07-19 2012-02-21 Sanovel İlaç San. Ve Ti̇c. A.Ş. Geliştirilmiş stabiliteye sahip prasugrel granülleri.
TR201007926A1 (tr) 2010-07-19 2012-02-21 Sanovel İlaç San.Ve Ti̇c.A.Ş. Prasugrel tablet formülasyonları.
CZ2011872A3 (cs) 2011-12-22 2013-07-03 Zentiva, K.S. Farmaceutická formulace prasugrelu hydrobromidu
US8603537B2 (en) 2012-04-02 2013-12-10 Egis Pharmaceuticals Plc Prasugrel containing quickly released stable oral pharmaceutical compositions
EP2722036A1 (en) 2012-10-19 2014-04-23 Sanovel Ilac Sanayi ve Ticaret A.S. Solid oral formulations of prasugrel
EP2722037A1 (en) 2012-10-19 2014-04-23 Sanovel Ilac Sanayi ve Ticaret A.S. Prasugrel formulations
CN102993210A (zh) * 2012-12-19 2013-03-27 苏春华 一种吡啶并噻吩的新化合物
EP2979693A1 (en) 2014-08-01 2016-02-03 Zaklady Farmaceutyczne Polpharma SA Pharmaceutical composition comprising prasugrel or pharmaceutically acceptable salt thereof and process for its preparation
WO2016122421A1 (en) 2015-01-29 2016-08-04 Pharmactive Ilaç Sanayi Ve Ticaret A.Ş. Stable pharmaceutical compositions containing prasugrel base
EP3158993A1 (en) 2015-10-22 2017-04-26 Zaklady Farmaceutyczne Polpharma SA Process for preparing a tablet comprising prasugrel or pharmaceutically acceptable salt thereof
CN107304216A (zh) * 2016-04-20 2017-10-31 陕西合成药业股份有限公司 噻吩吡啶类衍生物及其制备方法和用途
HU231079B1 (hu) 2016-06-23 2020-06-29 Richter Gedeon Nyrt. Eljárás nagytisztaságú Prasugrel előállítására bromopentil szennyezés eltávolításával
GR1009230B (el) 2016-10-12 2018-02-22 Φαρματεν Αβεε Φαρμακευτικο σκευασμα που περιλαμβανει βεσυλικη πρασουγρελη

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI101150B (fi) * 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
KR20090033917A (ko) * 2000-07-06 2009-04-06 다이이찌 산쿄 가부시키가이샤 히드로피리딘 유도체 산부가염
JP4001199B2 (ja) * 2000-07-06 2007-10-31 第一三共株式会社 ヒドロピリジン誘導体酸付加塩
EP1243524A3 (en) * 2001-03-16 2004-04-07 Pfizer Products Inc. Pharmaceutical kit for oxygen-sensitive drugs
JP4394873B2 (ja) * 2001-12-19 2010-01-06 武田薬品工業株式会社 酸素に不安定な化合物を含有する固形組成物およびその安定化方法
SI21302A (sl) * 2002-10-11 2004-04-30 LEK farmacevtska dru�ba d.d. Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino
US20050020554A1 (en) * 2003-06-06 2005-01-27 Ahmed Salah U. Stability of hormone formulations
RS20060081A (en) * 2003-08-05 2008-06-05 Zentiva A.S., Methods for the stabilization of atorvastatin

Also Published As

Publication number Publication date
BRPI0611350B8 (pt) 2021-05-25
UA91051C2 (ru) 2010-06-25
CA2611668A1 (en) 2006-12-21
PT1896019E (pt) 2009-11-19
US20080176893A1 (en) 2008-07-24
BRPI0611350B1 (pt) 2020-09-15
EP1896019A2 (en) 2008-03-12
HK1116422A1 (en) 2008-12-24
KR20080008413A (ko) 2008-01-23
BRPI0611350A2 (pt) 2010-12-07
DOP2006000126A (es) 2006-12-15
JP2008543755A (ja) 2008-12-04
TW200718420A (en) 2007-05-16
WO2006135605A3 (en) 2007-04-12
ECSP077984A (es) 2008-01-23
CN101193633B (zh) 2011-12-14
DE602006008942D1 (en) 2009-10-15
ATE441413T1 (de) 2009-09-15
MY151038A (en) 2014-03-31
EP1896019B1 (en) 2009-09-02
CN101193633A (zh) 2008-06-04
TWI318571B (en) 2009-12-21
CY1109502T1 (el) 2014-08-13
AU2006258102B2 (en) 2011-09-15
HRP20090516T1 (en) 2009-10-31
TNSN07466A1 (en) 2009-03-17
KR20100076050A (ko) 2010-07-05
NO20076317L (no) 2008-02-29
AU2006258102A1 (en) 2006-12-21
DK1896019T3 (da) 2009-10-26
EA200702670A1 (ru) 2008-04-28
EA011693B1 (ru) 2009-04-28
ES2330373T3 (es) 2009-12-09
PL1896019T3 (pl) 2010-01-29
WO2006135605A2 (en) 2006-12-21
MX2007015431A (es) 2008-02-21
IL187830A0 (en) 2008-04-13
CA2611668C (en) 2013-10-15
AR054283A1 (es) 2007-06-13
ZA200710697B (en) 2009-08-26
SI1896019T1 (sl) 2010-01-29
MA29688B1 (fr) 2008-08-01
PE20070320A1 (es) 2007-05-12
NZ564003A (en) 2011-07-29

Similar Documents

Publication Publication Date Title
RS51194B (sr) Formulacija tienopiridina kao inhibitora agregacije plateleta
DK1848659T3 (da) Oxygenopfangningssammensætninger og emballage omfattende sammensætningerne
HRP20080564T3 (en) Dihydrotetrabenazines and pharmaceutical compositions containing them
CY1115190T1 (el) Φαρμακοτεχνικες μορφες αερολυματων περιλαμβανοντας διενυδρη φουμαρικη φορμοτερολη, ενα προωθητικο, αιθανολη και προεραιτικως ενα στεροειδες, οπου η διενυδρη φουμαρικη φορμοτερολη εχει ενα περιεχομενο υδατος του 4,8-4.28% κατα βαρος
AR052853A1 (es) Composiciones orales que contienen compuestos antibacterianos de bifenol
CY1113267T1 (el) Παραγωγα θειοφαινιου ως αγωνιστες των υποδοσεων s1p1/edg1
RS52169B (sr) Stabilni preparati lakvinimoda
RS50629B (sr) Amidni prolek gemcitabina, kompozicije i njihova primena
NO20092417L (no) Kombinasjon av IAP-inhibitorer og FLT3-inhibitorer
ECSP088294A (es) Formulación en aerosol para la inhalación de beta-agonistas
CY1109737T1 (el) Νεα μεθοδος συνθεσης του (7-μεθοξυ-1-ναφθυλ) ακετονιτριλιου και εφαρμογη στη συνθεση της αγομελατινης
TR200401793T4 (tr) Perindopril tuzu ve bunu içeren farmasötik bileşimler.
RS51819B (sr) Stabilizovani farmaceutski preparat koji sadrži amorfnu aktivnu supstancu
PE20080381A1 (es) Fungicidas derivados de azolilmetiloxiranos y productos que los contienen
BRPI0413277A (pt) composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas
WO2003057205A3 (de) KOMBINATION VON MTP INHIBITOREN ODER apoB-SEKRETIONS-INHIBITOREN MIT FIBRATEN ZUR VERWENDUNG ALS ARZNEIMITTEL
FR2893924B1 (fr) Paquet d'articles comprenant un flanc le recouvrant partiellement et un film enveloppant le tout.
EA200700778A1 (ru) Блистерная упаковка для применения в ингаляторах
IL197887A0 (en) New fluorene derivatives, compositions containing the same and use thereof as inhibitors of the protein chaperone hsp 90
MA31678B1 (fr) Composition therapeutique aromatisee a base d'argile
EA200801572A1 (ru) Фармацевтическая композиция, содержащая аморфный аторвастатин
ATE324869T1 (de) Blisterverpackung und feste dosierungsform enthaltend desmopressin
EA200601632A1 (ru) Новая комбинация гетероциклического соединения и антиоксиданта и фармацевтические композиции, которые её содержат
TH87282B (th) สูตรผสมของสารยับยั้งการรวมกลุ่มของเกล็ดเลือดชนิดไทอีโนไพริดีน
FR2860500B1 (fr) Emballage de presentation et de stockage